Trial Profile

A Randomized, Phase II Trial of Circulating Tumor DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 16 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Fulvestrant (Primary) ; Palbociclib (Primary) ; Hormones
Indications Advanced breast cancer; Early breast cancer; HER2 negative breast cancer; Male breast cancer
Focus Therapeutic Use
Acronyms DARE
Sponsors Criterium

Most Recent Events

13 Jan 2025 Planned End Date changed from 15 Dec 2026 to 31 Dec 2027.
13 Jan 2025 Planned primary completion date changed from 15 Dec 2023 to 31 Dec 2027.
06 Dec 2023 According to a Natera media release, the association of this data with treatment benefit will be presented at future meetings.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com